Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

Autor: Rob E. Aarnoutse, Arianna D. Pranger, van der Tjipke Werf, D. van Soolingen, Jan-Willem C. Alffenaar, Jos G. W. Kosterink, Donald R. A. Uges, R. van Altena
Přispěvatelé: Faculteit Medische Wetenschappen/UMCG, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Targeted Gynaecologic Oncology (TARGON)
Rok vydání: 2011
Předmět:
Male
PHARMACOKINETICS
Moxifloxacin
Antitubercular Agents
rifampicin
Gastroenterology
Anti-Infective Agents
Drug Interactions
Netherlands
PLASMA
biology
medicine.diagnostic_test
Middle Aged
Treatment Outcome
tuberculosis
LONG QT SYNDROME
PHASE-II
Quinolines
Female
MYCOBACTERIUM-TUBERCULOSIS
Poverty-related infectious diseases Infectious diseases and international health [N4i 3]
medicine.drug
Fluoroquinolones
safety
Pulmonary and Respiratory Medicine
Adult
medicine.medical_specialty
Tuberculosis
PULMONARY TUBERCULOSIS
Mycobacterium tuberculosis
Invasive mycoses and compromised host [N4i 2]
CEREBROSPINAL-FLUID
Pharmacokinetics
Internal medicine
medicine
DRUGS
Humans
Tuberculosis
Pulmonary
Retrospective Studies
Aza Compounds
business.industry
Retrospective cohort study
Pathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]
IN-VITRO
medicine.disease
biology.organism_classification
Surgery
Discontinuation
Therapeutic drug monitoring
business
RESISTANCE
Rifampicin
Zdroj: European Respiratory Journal, 38, 4, pp. 888-94
European Respiratory Journal, 38, 888-94
European Respiratory Journal, 38(4), 888-894. EUROPEAN RESPIRATORY SOC JOURNALS LTD
ISSN: 0903-1936
DOI: 10.1183/09031936.00176610
Popis: Item does not contain fulltext Moxifloxacin (MFX) is a powerful second-line anti-tuberculosis (TB) agent, but the optimal dose has not yet been established and long-term safety data are scarce. We retrospectively reviewed the medical charts of TB patients treated at the Tuberculosis Centre Beatrixoord, University Medical Centre Groningen (Haren, the Netherlands) receiving MFX 400 mg once daily as part of their TB treatment between January 1 2006 and January 1 2009. Safety data and drug-drug interactions were evaluated. Efficacy was predicted based on the area under the concentration-time curve up to 24 h post-dosage (AUC(0-24h))/minimal inhibitory concentration (MIC) ratio. 89 patients were treated with a median dose of 6.9 mg . kg(-1) MFX once daily for a median period of 74 days. Discontinuation of therapy occurred in only three patients due to gastrointestinal side-effects and hypersensitivity. Pharmacokinetic analysis showed an AUC(0-24h)/MIC ratio /= 0.25 mg . L(-1)) to assess optimal therapy.
Databáze: OpenAIRE
Externí odkaz: